NEW YORK--(BUSINESS WIRE)--Neuro-Hitech, Inc. (NASDAQ: NHPI), a biopharmaceutical company focused on the development and commercialization of next-generation compounds against proven targets for neurodegenerative diseases, today announced that the Alzheimer’s Disease Research program of the American Health Assistance Foundation (AHAF) has recently awarded Donald Weaver, M.D., Ph.D., of Dalhousie University, Halifax, Nova Scotia, Canada, a grant for $1 million dollars to fund further research with respect to compounds licensed to the Company.
